Pharmacophore definition and three-dimensional quantitative structure-activity relationship study on structurally diverse prostacyclin receptor agonists.
暂无分享,去创建一个
Hans-Dieter Höltje | Thomas Hohlfeld | K. Schrör | T. Hohlfeld | P. Fuchs | H. Höltje | Karsten Schrör | Friederike Stoll | Sven Liesener | Philip L Fuchs | F. Stoll | S. Liesener
[1] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[2] R. Stehle. [56] Physical chemistry, stability, and handling of prostaglandins E2, F2α, D2, and I2: A critical summary , 1982 .
[3] N. Meanwell,et al. Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moiety. , 1992, Journal of medicinal chemistry.
[4] J. Macdermot,et al. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics , 1986, British journal of pharmacology.
[5] H. Vorbrüggen,et al. Synthesis of ciloprost (ZK 36 374): a chemically stable and biologically potent prostacyclin analog. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.
[6] C. Lemmen,et al. FLEXS: a method for fast flexible ligand superposition. , 1998, Journal of medicinal chemistry.
[7] L. Audoly,et al. Substitution of charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction of the prostaglandin EP3 receptor. , 1997, Molecular pharmacology.
[8] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.
[9] Hans-Dieter Höltje,et al. Structure-based 3D-QSAR—merging the accuracy of structure-based alignments with the computational efficiency of ligand-based methods , 2000 .
[10] Ah-lim Tsai,et al. Conformation of receptor-associated PGI2: An investigation by molecular modeling , 1991, J. Comput. Aided Mol. Des..
[11] Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified beta-to the oxazole ring. , 1994, Drug design and discovery.
[12] Y. Sugimoto,et al. Selective Coupling of Prostaglandin E Receptor EP3D to Gi and Gs through Interaction of α-Carboxylic Acid of Agonist and Arginine Residue of Seventh Transmembrane Domain (*) , 1995, The Journal of Biological Chemistry.
[13] Thomas Lengauer,et al. Time-efficient flexible superposition of medium-sized molecules , 1997, German Conference on Bioinformatics.
[14] Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring. , 1993, Journal of medicinal chemistry.
[15] A. Ichikawa,et al. Functional interaction of the carboxylic acid group of agonists and the arginine residue of the seventh transmembrane domain of prostaglandin E receptor EP3 subtype. , 1997, The Biochemical journal.
[16] L. Audoly,et al. A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding. , 1998, European journal of pharmacology.
[17] M Pastor,et al. Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. , 1997, Journal of medicinal chemistry.
[18] J. Regan,et al. A single amino-acid substitution in the EP2 prostaglandin receptor confers responsiveness to prostacyclin analogs. , 1998, Molecular pharmacology.
[19] N. Meanwell,et al. Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic. , 1992, Journal of medicinal chemistry.
[20] N. Meanwell,et al. Non-prostanoid prostacyclin mimetics , 1994 .
[21] N. Meanwell,et al. Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives. , 1992, Journal of medicinal chemistry.
[22] N. Meanwell,et al. Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid. , 1993, Journal of medicinal chemistry.
[23] Robin Taylor,et al. IsoStar: A library of information about nonbonded interactions , 1997, J. Comput. Aided Mol. Des..
[24] P. Fuchs,et al. Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets. , 1994, Prostaglandins.
[25] Thomas Lengauer,et al. RigFit: A new approach to superimposing ligand molecules , 1998, German Conference on Bioinformatics.
[26] K. Schrör,et al. The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia , 1993, European Journal of Clinical Pharmacology.
[27] J. Gasteiger,et al. ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .
[28] R. Armstrong. Platelet prostanoid receptors. , 1996, Pharmacology & therapeutics.
[29] H. Tai,et al. Expression and site-directed mutagenesis of mouse prostaglandin E2 receptor EP3 subtype in insect cells. , 1995, The Biochemical journal.